Hypothyroid patients are usually treated with in an oral administration of 1-T4. When oral administration is impossible because of esophageal stenosis or unconsciousness in such patients, parenteral replacement is required. We prepared a solution of 1-T4 50 micrograms/ml for intravenous administration in Tohoku University Hospital as follows: 5mg of 1-T4 (Nakarai Co.) was dissolved in 1ml of 0.1N NaOH and diluted with 0.9% NaCl and sterilized with membrane filter. Two patients with esophageal stenosis due to thyroid cancer and esophageal cancer and one in a coma due to adrenal crisis had replacement with intravenous 1-T4. Initial doses of 12.5 micrograms or 25 micrograms diluted with 100ml of 0.9% NaCl containing 1% albumin were given by drip infusion. Every week 12.5 micrograms or 25 micrograms of 1-T4 was increased. By replacement of low doses, 50 micrograms or 75 micrograms, serum T4 reached a normal level. No adverse action was observed during or after parenteral replacement. The preparation of 1-T4 was stable at least for one year and 11 months. Parenteral replacement of T4 is a useful and safe method for patients who are unable to take drugs orally.
[1]
G. Royle,et al.
Treatment with intravenous triiodothyronine of colonic pseudo‐obstruction caused by myxoedema
,
1981,
The British journal of surgery.
[2]
N. Kuzuya,et al.
Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism.
,
1976,
The Journal of clinical endocrinology and metabolism.
[3]
J. Ljunggren,et al.
Subcutaneous administration of sodium l-thyroxine to patients with hypothyroidism.
,
2009,
Acta medica Scandinavica.
[4]
D. Solomon,et al.
Reciprocal Changes in Serum Concentrations of 3,3′,5′-Triiodothyronine (Reverse T3) and 3,3′5-Triiodothyronine (T3) in Systemic Illnesses
,
1975
.
[5]
W. C. Ball,et al.
Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.
,
1972,
Annals of internal medicine.